GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Cyclically Adjusted PS Ratio

CytoSorbents (CytoSorbents) Cyclically Adjusted PS Ratio : 1.26 (As of Jun. 07, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Cyclically Adjusted PS Ratio?

As of today (2024-06-07), CytoSorbents's current share price is $0.884. CytoSorbents's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.70. CytoSorbents's Cyclically Adjusted PS Ratio for today is 1.26.

The historical rank and industry rank for CytoSorbents's Cyclically Adjusted PS Ratio or its related term are showing as below:

CTSO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.15   Med: 22.35   Max: 73.7
Current: 1.26

During the past years, CytoSorbents's highest Cyclically Adjusted PS Ratio was 73.70. The lowest was 1.15. And the median was 22.35.

CTSO's Cyclically Adjusted PS Ratio is ranked better than
65.34% of 476 companies
in the Medical Devices & Instruments industry
Industry Median: 2.16 vs CTSO: 1.26

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CytoSorbents's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.166. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.70 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CytoSorbents Cyclically Adjusted PS Ratio Historical Data

The historical data trend for CytoSorbents's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Cyclically Adjusted PS Ratio Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.45 19.24 8.31 2.57 1.63

CytoSorbents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.37 5.51 2.80 1.63 1.35

Competitive Comparison of CytoSorbents's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, CytoSorbents's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CytoSorbents's Cyclically Adjusted PS Ratio falls into.



CytoSorbents Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

CytoSorbents's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.884/0.7
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoSorbents's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CytoSorbents's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.166/131.7762*131.7762
=0.166

Current CPI (Mar. 2024) = 131.7762.

CytoSorbents Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.055 100.560 0.072
201409 0.083 100.428 0.109
201412 0.038 99.070 0.051
201503 0.029 99.621 0.038
201506 0.027 100.684 0.035
201509 0.043 100.392 0.056
201512 0.060 99.792 0.079
201603 0.063 100.470 0.083
201606 0.073 101.688 0.095
201609 0.084 101.861 0.109
201612 0.103 101.863 0.133
201703 0.102 102.862 0.131
201706 0.109 103.349 0.139
201709 0.122 104.136 0.154
201712 0.149 104.011 0.189
201803 0.151 105.290 0.189
201806 0.173 106.317 0.214
201809 0.163 106.507 0.202
201812 0.173 105.998 0.215
201903 0.143 107.251 0.176
201906 0.181 108.070 0.221
201909 0.177 108.329 0.215
201912 0.204 108.420 0.248
202003 0.240 108.902 0.290
202006 0.261 108.767 0.316
202009 0.246 109.815 0.295
202012 0.267 109.897 0.320
202103 0.235 111.754 0.277
202106 0.262 114.631 0.301
202109 0.205 115.734 0.233
202112 0.223 117.630 0.250
202203 0.182 121.301 0.198
202206 0.168 125.017 0.177
202209 0.148 125.227 0.156
202212 0.175 125.222 0.184
202303 0.181 127.348 0.187
202306 0.183 128.729 0.187
202309 0.175 129.860 0.178
202312 0.158 129.419 0.161
202403 0.166 131.776 0.166

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CytoSorbents  (NAS:CTSO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


CytoSorbents Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoSorbents (CytoSorbents) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Executives
Edward Raymond Jones director 70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch officer: Chief Financial Officer 3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi officer: Chief Operating Officer MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan director, officer: President and CEO 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim director C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel director 293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator director C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico officer: Chief Financial Officer 10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus director MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen officer: Chief Medical Officer C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp 10 percent owner 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley 10 percent owner 9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger officer: See Remarks 7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino officer: Chief Financial Officer C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852